The Company has a limited number of compounds in the portfolio in different stages of development. New drug development programs could not be started without VC funds. However, there may be a chance to accelerate several programs and slow down others, depending on the current and projected status of the program, scientific results, etc. Therefore, the Company’s goal is to minimize the amount of money to be raised (to preserve equity for owners) and simultaneously not jeopardize the execution of projects.

ORBee Consulting analysis saved the Company ~ 15% of the three-year budget.